In summary, this work shows that IL-4/IL-13 stimulated M2a macrophages are the most potent enhancers of breast cancer migratory and invasive phenotypes and thus the sub-population most likely to have anti-cancer effects if targeted as a single modality or in combination with anti-PD-1 or anti-PD-L1 antibodies, to help prime the TME for immune therapies. Here, CD274 is linked to breast carcinoma.